From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit.

Biomedical Research Carcinoma, Renal Cell / diagnosis Female Genomics Humans Kidney Neoplasms / diagnosis Male

Journal

Clinical cancer research : an official journal of the American Association for Cancer Research
ISSN: 1557-3265
Titre abrégé: Clin Cancer Res
Pays: United States
ID NLM: 9502500

Informations de publication

Date de publication:
01 03 2022
Historique:
received: 07 09 2021
revised: 07 11 2021
accepted: 21 12 2021
pubmed: 31 12 2021
medline: 16 4 2022
entrez: 30 12 2021
Statut: ppublish

Résumé

The second Kidney Cancer Research Summit was held virtually in October 2020. The meeting gathered worldwide experts in the field of kidney cancer, including basic, translational, and clinical scientists as well as patient advocates. Novel studies were presented, addressing areas of unmet need related to different topics. These include novel metabolic targets, promising immunotherapeutic regimens, predictive genomic and transcriptomic biomarkers, and variant histologies of renal cell carcinoma (RCC). With the development of pioneering technologies, and an unprecedented commitment to kidney cancer research, the field has tremendously evolved. This perspective aims to summarize the different sessions of the conference, outline major advances in the understanding of RCC and discuss current challenges faced by the field.

Identifiants

DOI: 10.1158/1078-0432.CCR-21-3238 PMID: 34965942 PMC: PMC9223120
pubmed: 34965942
pii: 1078-0432.CCR-21-3238
doi: 10.1158/1078-0432.CCR-21-3238
pmc: PMC9223120
mid: NIHMS1814788
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

831-839

Subventions

Organisme : NCI NIH HHS
ID : P50 CA101942
Pays : United States
Organisme : NCI NIH HHS
ID : R35 CA210068
Pays : United States

Informations de copyright

©2021 American Association for Cancer Research.

Références

Cell. 2017 Dec 14;171(7):1678-1691.e13
pubmed: 29245013
Bull Cancer. 2020 Jun;107(5S):eS22-eS27
pubmed: 32620212
N Engl J Med. 2003 Jul 31;349(5):427-34
pubmed: 12890841
Nat Commun. 2020 May 1;11(1):2135
pubmed: 32358509
Nat Genet. 2015 Jan;47(1):13-21
pubmed: 25401301
Cancer Immunol Immunother. 2021 Oct;70(10):2881-2892
pubmed: 33751180
Nat Med. 2021 May;27(5):802-805
pubmed: 33888901
J Natl Cancer Inst. 2021 Mar 1;113(3):234-243
pubmed: 32359162
Cancer Discov. 2019 Apr;9(4):476-481
pubmed: 30862723
Science. 2015 May 15;348(6236):803-8
pubmed: 25837513
Nat Cell Biol. 2018 Oct;20(10):1181-1192
pubmed: 30202049
Nat Cell Biol. 2019 Dec;21(12):1604-1614
pubmed: 31792381
JAMA Oncol. 2020 Aug 1;6(8):1247-1255
pubmed: 32469384
Int J Mol Sci. 2017 Feb 14;18(2):
pubmed: 28216575
N Engl J Med. 2021 Mar 4;384(9):829-841
pubmed: 33657295
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Rev Cancer. 2009 Mar;9(3):153-66
pubmed: 19238148
Science. 2018 Feb 16;359(6377):801-806
pubmed: 29301960
Cancer Res. 2016 Apr 1;76(7):1892-903
pubmed: 26833124
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32661118
Mol Cancer. 2018 Feb 19;17(1):45
pubmed: 29455668
Cancer Epidemiol. 2018 Jun;54:112-118
pubmed: 29715680
J Clin Oncol. 2018 Oct 29;:JCO2018792531
pubmed: 30372389
Nat Med. 2019 Aug;25(8):1251-1259
pubmed: 31359002
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Mol Cell Oncol. 2018 Nov 13;6(1):1536845
pubmed: 30788415
Clin Cancer Res. 2018 May 1;24(9):2044-2049
pubmed: 29440190
J Clin Oncol. 2018 Mar 20;36(9):867-874
pubmed: 29257710
Nat Cancer. 2020 Feb;1(2):210-221
pubmed: 32110781
Genome Med. 2020 Feb 28;12(1):23
pubmed: 32111235
Cancer Cell. 2021 May 10;39(5):632-648.e8
pubmed: 33711273
Cancer Immunol Res. 2018 Jul;6(7):758-765
pubmed: 29748390
Nat Rev Clin Oncol. 2014 Feb;11(2):81-90
pubmed: 24281059
Cancer Discov. 2021 May;11(5):1040-1051
pubmed: 33687987
Cell Rep. 2022 Jan 4;38(1):110190
pubmed: 34986355
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
Nat Med. 2020 Oct;26(10):1519-1530
pubmed: 33020645
Signal Transduct Target Ther. 2019 Jan 25;4:2
pubmed: 30701095
Nat Rev Nephrol. 2020 Jan;16(1):2
pubmed: 31628435
JAMA Oncol. 2016 May 01;2(5):664-667
pubmed: 27010573
J Clin Invest. 2008 Mar;118(3):1099-109
pubmed: 18292810
Hum Pathol. 2015 May;46(5):673-80
pubmed: 25704627
Immunity. 2019 Jan 15;50(1):181-194.e6
pubmed: 30635236
Clin Cancer Res. 2014 Aug 1;20(15):4129-40
pubmed: 24899691
Neoplasia. 2018 Jun;20(6):610-620
pubmed: 29747161
Eur J Cancer. 2019 Jan;106:133-143
pubmed: 30528798
Nat Rev Clin Oncol. 2021 Apr;18(4):199-214
pubmed: 33437048
Cancer Cell. 2020 Dec 14;38(6):803-817.e4
pubmed: 33157048
J Thorac Oncol. 2020 Apr;15(4):589-600
pubmed: 31887430
J Clin Oncol. 2021 Mar 20;39(9):1029-1039
pubmed: 33529058
Cancer Cell. 2020 May 11;37(5):720-734.e13
pubmed: 32359397
Cells. 2018 Sep 15;7(9):
pubmed: 30223576
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
Int J Urol. 2011 Jan;18(1):63-71
pubmed: 21091798
Cell Res. 2021 Feb;31(2):107-125
pubmed: 33268902
Nature. 2021 Jul;595(7867):432-437
pubmed: 34135506
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32493845
Sci Signal. 2019 Oct 01;12(601):
pubmed: 31575731
JCI Insight. 2018 Aug 23;3(16):
pubmed: 30135306
J Immunother Cancer. 2020 Jun;8(1):
pubmed: 32601081
Nature. 2019 Jan;565(7738):240-245
pubmed: 30568303
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Cancer Cell. 2021 May 10;39(5):649-661.e5
pubmed: 33711272
Clin Cancer Res. 2020 Jul 15;26(14):3629-3640
pubmed: 32220885
Int J Mol Sci. 2020 Dec 23;22(1):
pubmed: 33374804
N Engl J Med. 2017 Dec 21;377(25):2500-2501
pubmed: 29262275
Nat Med. 2020 Jun;26(6):909-918
pubmed: 32472114
Cell Rep. 2018 Mar 13;22(11):2978-2994
pubmed: 29539425
Nat Commun. 2020 Aug 20;11(1):4168
pubmed: 32820162
Nat Med. 2020 Nov;26(11):1733-1741
pubmed: 32895571
J Hematol Oncol. 2020 Jun 29;13(1):83
pubmed: 32600443
Nat Commun. 2020 Jun 18;11(1):3096
pubmed: 32555180
Nat Med. 2020 Jul;26(7):1041-1043
pubmed: 32572266
Cancer Cell. 2021 May 10;39(5):662-677.e6
pubmed: 33861994
Mol Diagn Ther. 2020 Aug;24(4):375-396
pubmed: 32323260
Front Oncol. 2019 Jun 14;9:490
pubmed: 31259150
J Biol Chem. 2020 Nov 13;295(46):15636-15649
pubmed: 32883810
EBioMedicine. 2019 Mar;41:427-442
pubmed: 30827930
Genet Med. 2020 Aug;22(8):1366-1373
pubmed: 32341571
Cancer Immunol Res. 2021 Jan;9(1):103-112
pubmed: 33177107
Proc Natl Acad Sci U S A. 2018 Jul 3;115(27):E6274-E6282
pubmed: 29891694
Clin Cancer Res. 2019 Nov 15;25(22):6598-6605
pubmed: 31439579
Cancer Discov. 2020 Mar;10(3):460-475
pubmed: 31810986
PLoS One. 2021 Apr 21;16(4):e0245415
pubmed: 33882057
Nat Med. 2018 Jun;24(6):749-757
pubmed: 29867230
Nature. 2020 Mar;579(7798):274-278
pubmed: 32103181
Cancer Treat Rev. 2021 Sep;99:102228
pubmed: 34111642
Nat Rev Clin Oncol. 2021 Mar;18(3):133-134
pubmed: 33299070
Nat Rev Urol. 2014 Aug;11(8):465-75
pubmed: 25048860
JAMA Oncol. 2019 Nov 1;5(11):1631-1633
pubmed: 31486842
Nat Rev Clin Oncol. 2021 Apr;18(4):244-256
pubmed: 33277626
Nat Genet. 2012 Jun 10;44(7):751-9
pubmed: 22683710
Nat Metab. 2020 Mar;2(3):270-277
pubmed: 32462112
Nat Chem Biol. 2013 Apr;9(4):271-6
pubmed: 23434853
Nat Commun. 2021 Feb 5;12(1):808
pubmed: 33547292
Cancer Discov. 2020 Mar;10(3):348-350
pubmed: 32127406

Auteurs

Toni K Choueiri (TK)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Laurence Albiges (L)

Department of Medical Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Michael B Atkins (MB)

Georgetown Lombardi Comprehensive Cancer Center, Washington, DC.
ORCID: 0000-0003-3901-9924

Ziad Bakouny (Z)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
ORCID: 0000-0003-1906-5704

Gennady Bratslavsky (G)

Department of Urology, State University of New York (SUNY) Upstate Medical University, Syracuse, New York.
ORCID: 0000-0002-2712-4375

David A Braun (DA)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Naomi B Haas (NB)

Division of Hematology and Oncology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
ORCID: 0000-0001-8907-7968

John B A G Haanen (JBAG)

Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, the Netherlands.

A Ari Hakimi (AA)

Department of Surgery, Urology Service, Memorial Sloan Kettering Cancer Center, New York, New York.

Michael A S Jewett (MAS)

Division of Urology, Department of Surgery, Princess Margaret Cancer Centre, Toronto, Ontario, Canada.
ORCID: 0000-0001-7162-5380

Eric Jonasch (E)

Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

William G Kaelin (WG)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.

Payal Kapur (P)

Department of Pathology, University of Texas Southwestern Medical Center, Dallas, Texas.
ORCID: 0000-0002-4239-0495

Chris Labaki (C)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
ORCID: 0000-0002-9584-8455

Bryan Lewis (B)

KidneyCAN, Philadelphia, Pennsylvania.

David F McDermott (DF)

Division of Medical Oncology, Beth Israel Deaconess Medical Center, Dana-Farber/Harvard Cancer Center, Boston, Massachusetts.

Sumanta K Pal (SK)

Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.

Kevin Pels (K)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
ORCID: 0000-0002-3214-379X

Susan Poteat (S)

KidneyCAN, Philadelphia, Pennsylvania.

Thomas Powles (T)

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.

W Kimryn Rathmell (WK)

Department of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.
ORCID: 0000-0002-4984-0225

Brian I Rini (BI)

Department of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, Tennessee.

Sabina Signoretti (S)

Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.
ORCID: 0000-0002-5000-9105

Nizar M Tannir (NM)

Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Robert G Uzzo (RG)

Department of Surgical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania.

Hans J Hammers (HJ)

Division of Hematology-Oncology, University of Texas Southwestern Medical Center, Dallas, Texas.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Disciplines des sciences naturelles › Science › Recherche › Recherche biomédicale › From Basic Science to Clinical Translation in...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › Néphrocarcinome › From Basic Science to Clinical Translation in...
questionsmedicales.fr › Disciplines des sciences naturelles › Disciplines des sciences biologiques › Biologie › Génétique › Génomique › From Basic Science to Clinical Translation in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › From Basic Science to Clinical Translation in...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs du rein › From Basic Science to Clinical Translation in...